Think out of the box to scale up Covaxin production

Instead of waiting for the WTO negotiations to conclude, why can’t India widely share the technology and the knowhow of Covaxin within the country so as to scale up production?

Published: 12th May 2021 11:25 PM  |   Last Updated: 13th May 2021 12:10 AM   |  A+A-


A health official shows a Covaxin vaccine dose at a hospital in New Delhi. (Photo | Shekhar Yadav, EPS)

With the Centre decentralising and liberalising their vaccination policy, more than 10 states have decided to float global tenders for foreign Covid jabs to vaccinate its population in the 18-44 age group. That is the category the policy says the Centre will not cover under its free vaccination programme, so the burden of inoculating them for free is on the states. Global shopping began because domestic manufacturers Serum Institute of India (SII) and Bharat Biotech are struggling to meet even the needs of the 45+ group that the Centre is committed to funding for vaccination. The 45+ is the priority group since 85% of all Covid deaths during the first wave happened in that section of the population. But the question is which foreign manufacturer other than Russia’s Sputnik V is prepared to sell at short notice, given the huge back orders they already have from the global North. The Centre, in its recent affidavit, told the Supreme Court that it is in active discussions with Pfizer, Moderna, J&J and other vaccine developers/manufacturers outside India to facilitate imports. But it qualified its statement by saying “if these efforts are successful”, the pace of vaccination can go up. That is a big ‘if’. Besides, countries like the US have just opened up vaccination for their adolescents, so their requirement will only go up, leaving little room for their pharma majors to export their jabs in the short run.

Union Minister Piyush Goyal on Wednesday sought a quick consensus at the World Trade Organization on patent waiver, transfer of technology and making raw materials for vaccines available to scale up global production. Instead of waiting for the WTO negotiations to conclude, why can’t India widely share the technology and the knowhow of Covaxin—the only indigenously developed vaccine by the Centre in collaboration with Bharat Biotech—within the country so as to scale up production? Deals to manufacture Covaxin have already been done with three Indian companies, but why restrict it to them and not expand the ambit to whichever domestic manufacturer is ready to pitch in? That could be a new model on internal patent waiver to meet the pandemic demand of the global South in what we proudly call the pharmacy of the world.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

  • Rahul

    Manufacturing of Covaxin is not as easy as said. It is based on dead virus and requires BSL3 facility. Making a BSL3 compliant facility is the first challenge then comes the Covaxin production part. There are few facilities in India which are BSL3 and all have got a go ahead for Covaxin production. Even a PSU is getting updated to BSL3 for which decision was taken last year itself. How many private parties will invest in making a BSL3 facility for a short run of Covaxin production (which will eventually be purchased at a subsidized rate only)? So do a bit of homework before writing editorials. This out of box is actually out of reality.
    1 year ago reply
flipboard facebook twitter whatsapp